Dr. Small is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1825 4th St
San Francisco, CA 94143Phone+1 415-476-4616Fax+1 415-353-7107- Is this information wrong?
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1989
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
- Case Western Reserve University School of MedicineClass of 1985
Certifications & Licensure
- CA State Medical License 1987 - 2024
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Start of enrollment: 1994 Sep 01
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Start of enrollment: 1995 May 01
- Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.Hewitt Chang, Jaqueline Marquez, Brandon K Chen, Daniel M Kim, Michael L Cheng, Eric V Liu, Hai Yang, Li Zhang, Meenal Sinha, Alexander Cheung, Serena S Kwek, Eric D C...> ;Cancer Immunology Research. 2024 Apr 2
- Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).Jai N Patel, Chen Jiang, Kouros Owzar, Daniel L Hertz, Janey Wang, Flora A Mulkey, William K Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G Dorsey, Pa...> ;The Pharmacogenomics Journal. 2024 Mar 4
- Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced P...Chi, K., Chowdhury, S., Bevans, K., Bhaumik, A., Saad, F., Chung, B., Oudard, S., De Porre, P., Brookman-May, S., McCarthy, S., Mundle, S., Uemura, H., Small, E., Kars...> ;European Urology Oncology. 2023 Dec 9
- Join now to see all
Journal Articles
- First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate CancerSpencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
- Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEric J Small, David I Quinn, Clinical Cancer Research
Authored Content
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
- Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018
Press Mentions
- NEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to Its Board of Directors and Scientific Advisory BoardAugust 23rd, 2021
- Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate CancerFebruary 14th, 2019
- UCSF and MGH: Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate CancerFebruary 8th, 2018
- Join now to see all
Grant Support
- Prostate Cancer ProgramNational Cancer Institute2007–2011
- 04557: A Phase I/II Study Of Docetaxel/Prednisone And PTK 787/Zk 222584 In PRNational Center For Research Resources2005
- Effects Of Bicalutamide Monotherapy On Bone Density In Prostate CancerNational Center For Research Resources2004–2005
- Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CarcinomaNational Center For Research Resources1997
- Study Of Pyrazoloacridine For Treatment Of Hormone Refractory Prostate CancerNational Center For Research Resources1996–1997
- Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CancerNational Center For Research Resources1996
Hospital Affiliations
- UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: